JESSICA TEMM: Open Payments
NPI 1487391520 · JOPLIN, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$427 in 22 payments from 14 companies in 2025. Trend: 2023 $851 · 2024 $791 · 2025 $427
Food & beverage: $427
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 3 | $59 |
| GENZYME CORPORATION | 2 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $36 |
| Aimmune Therapeutics, Inc. | 2 | $35 |
| ABBVIE INC. | 2 | $31 |
| Lilly USA, LLC | 1 | $27 |
| Madrigal Pharmaceuticals | 1 | $19 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
Products named: DUPIXENT, XELJANZ, XIFAXAN, OMVOH, ENTYVIO, REZDIFFRA, ZENPEP, TEZSPIRE.
Industry payments across MO — which companies pay providers there.
